Amphastar Pharmaceuticals (AMPH) Q2 2024 earnings summary

Executive summary

• Net revenues for Q2 2024 increased 25% year-over-year to $182.4 million, driven by strong sales of BAQSIMI®, Primatene MIST®, and epinephrine, reflecting a strategic focus on branded products, biosimilars, and complex generics.

• BAQSIMI® sales reached $38.5 million, up 10% year-over-year, with direct distribution transition from Lilly boosting international presence in over 26 countries.

• Operational efficiencies, manufacturing capacity enhancements, and a fully integrated business model supported growth and future demand.

• The company continues to expand its diabetes portfolio and pipeline, including GLP-1 and interchangeable insulins.

• FDA approved Albuterol Sulfate Inhalation Aerosol in May 2024, with launch planned for Q3 2024.

Financial highlights

• Q2 2024 net revenues: $182.4M (+25% YoY); net income: $37.9M (up 45% YoY); adjusted net income: $48.7M ($0.94 per share); gross margin improved to 52.2% from 49.9% YoY.

• Primatene MIST® sales grew 38% to $22.9M; epinephrine sales rose 67% to $27.9M year-over-year.

• Operating cash flow for the first six months of 2024 was $124.4M; cash and equivalents at June 30, 2024: $189.6M.

• Share repurchases of $8.5M and mortgage paydown of $8M during the quarter; $129M payment made for BAQSIMI® acquisition.

• R&D expenses for Q2 2024 were $17.7M (+5% YoY); six-month R&D: $34.7M (-5% YoY).

Outlook and guidance

• Anticipates three significant product approvals in the second half of 2024: teriparatide (AMP-015), AMP-007, and AMP-002.

• BAQSIMI® projected to reach peak annual sales of $250M–$275M, with incremental adjusted EPS of $2.00–$2.50 at peak.

• Expects continued BAQSIMI® growth, with most country transitions to direct distribution completed by Q4 2024.

• R&D expenses projected to rise annually due to clinical trials for insulin and inhalation candidates.

• API segment sales expected to remain below historical levels for next two years as major customer qualifies upgraded product.